Table II.
E-cadherin and vimentin expression in patients with adenocarcinoma in the apparent MPP component group and no MPP component group.
| Apparent MPP component group (n=18) | ||||
|---|---|---|---|---|
|
|
||||
| Antibody | Grade | MPP component | Component without MPP | No MPP group (n=26) |
| E-cadherin | 3+ | 18 | 18 | 21 |
| 2+ | 0 | 0 | 5 | |
| 1+ | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| 3+ | 9 | 2 | 6 | |
| Vimentin | 2+ | 7 | 3 | 3 |
| 1+ | 2 | 1 | 4 | |
| 0 | 0 | 12a | 13a | |
Grade of expression was defined according to the proportion of positive cells as follows: 0, p<5% positive cells; 1+, 5≤p<30% positive cells; 2+, 30≤p<70% positive cells; 3+, p≥70% positive cells.
a
P<0.05 vs. MPP component in apparent MPP component group.
MPP, micropapillary pattern.